Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
PaperCitations, authors & open-access status
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 129 citations, 2019 year and closed oa status.
129
Citations
2019
Year
closed
OA Status